GuruFocus·Aug 25, 2026
Woodside Energy Half-Year Report for Period Ended 30 June 2026Woodside Energy Group (ASX: WDS) (NYSE: WDS):This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824
Aptorum Group faces a precarious outlook as its transition to a pre-revenue biotechnology model has resulted in the total evaporation of quarterly revenue compared to historical periods.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
Woodside Energy Group (ASX: WDS) (NYSE: WDS):This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824
- Delivery of the world's largest APM system for airports, supporting the airport development plan to accommodate 260 million passengers annually- MHI Group is
Benchmark NIKI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Niki BioSolutions, Inc. (NIKI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.58 | $128.67K | -0.08 | — | — | -10.66% | — | |
| $25.48 | $2.88B | -14.43 | 15.33% | -44.91% | -31.15% | — | |
| $10.78 | $1.77B | -23.17 | 64.69% | -18.64% | — | — | |
| $12.37 | $154.54M | -52.77 | 14.52% | -7.12% | -74.71% | — | |
| $1.83 | $14.82M | -1.58 | -13.27% | -24.76% | -52.89% | — | |
| $4.82 | $2.5B | 216.14 | 40.34% | 0.45% | 3.52% | — |
Niki BioSolutions, Inc. (NIKI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NIKI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Niki BioSolutions, Inc. (NIKI) stock FAQ — growth, dividends, profitability & financials explained
No. Niki BioSolutions, Inc. (NIKI) reported a net loss of $1.4M in fiscal year 2025.
Niki BioSolutions, Inc. (NIKI) had a return on equity (ROE) of -10.7% in fiscal year 2025. A negative ROE means the company lost money over the period.
Niki BioSolutions, Inc. (NIKI) had negative free cash flow of $1.8M in fiscal year 2025.
